Arch Biopartners Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACHFF research report →
Companywww.archbiopartners.com
Arch Biopartners Inc. , a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19.
- CEO
- Richard Gabriel Muruve
- IPO
- 2002
- Employees
- 6
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $21.31M
- P/E
- -10.91
- P/S
- 0.00
- P/B
- -8.17
- EV/EBITDA
- -13.53
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 72.34%
- ROIC
- 258.19%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-1,552,744 · 60.39%
- EPS
- $-0.02 · 61.65%
- Op Income
- $-1,499,812
- FCF YoY
- 31.95%
Performance & Tape
- 52W High
- $1.42
- 52W Low
- $0.29
- 50D MA
- $0.38
- 200D MA
- $0.76
- Beta
- 2.05
- Avg Volume
- 25.17K
Get TickerSpark's AI analysis on ACHFF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ACHFF Coverage
We haven't published any research on ACHFF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACHFF Report →